

Association Between Vascular 18F-Fluorodeoxyglucose Uptake at
Diagnosis and Change in Aortic Dimensions in Giant Cell Arteritis: A
Cohort Study

Peer-reviewed author version

Moreel, Lien; Coudyzer, Walter; Boeckxstaens, Lennert; Betraains, Albrecht;
MOLENBERGHS, Geert; Vanderschueren, Steven; Claus, Eveline; Van Laere, Koen
& Blockmans, Daniel (2023) Association Between Vascular 18F-Fluorodeoxyglucose
Uptake at Diagnosis and Change in Aortic Dimensions in Giant Cell Arteritis: A
Cohort Study. In: ANNALS OF INTERNAL MEDICINE, 176 (10) , p. 1321 -1329.

DOI: 10.7326/M23-0679

Handle: <http://hdl.handle.net/1942/41747>

1 **Association between vascular FDG uptake at diagnosis and**
2 **evolution in aortic dimensions in giant cell arteritis: a**
3 **prospective study**

4 **Lien Moreel, MD^{1,2}, Walter Coudyzer³, Lennert Boeckstaens, MD⁴, Albrecht Betrains,**
5 **MD^{1,2}, Geert Molenberghs, PhD⁵, Steven Vanderschueren, MD PhD^{1,2,6}, Eveline Claus,**
6 **MD³, Koen Van Laere, MD, PhD, DrSc^{4,7}, Daniel Blockmans, MD PhD^{1,2,6}**

7 ¹ Department of General Internal Medicine, University Hospitals Leuven, Leuven, Belgium

8 ² Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven,
9 Belgium

10 ³ Department of Radiology, University Hospitals Leuven, Belgium

11 ⁴ Division of Nuclear Medicine, University Hospitals Leuven, Belgium

12 ⁵ Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), University
13 of Leuven and Hasselt University, Leuven, Belgium

14 ⁶ European Reference Network for Immunodeficiency, Autoinflammatory, Autoimmune and
15 Pediatric Rheumatic disease (ERN-RITA)

16 ⁷ Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU
17 Leuven, Belgium

18
19 **Corresponding author:** Daniel Blockmans, Daniel.Blockmans@uzleuven.be, General
20 Internal Medicine department, University Hospitals Leuven, Herestraat 49, 3000 Leuven,
21 Belgium, ORCID-ID 0000-0002-7613-4801

22
23 **Word count:** 3487

24
25 **Keywords:** Giant cell arteritis – GCA – PET – aorta – aneurysm

26
27

28 **Abstract**

29 **Background:** Retrospective studies have shown that giant cell arteritis (GCA) patients with
30 vascular 18F-fluorodeoxyglucose (FDG) uptake at diagnosis are at increased risk of
31 developing aortic complications.

32 **Objective:** To evaluate the association between vascular FDG uptake at diagnosis and the
33 evolution of aortic dimensions in GCA patients.

34 **Design:** Prospective cohort study

35 **Setting:** University Hospitals Leuven, 2012-2020

36 **Patients:** 100 GCA patients with FDG PET imaging at diagnosis ≤ 3 days after initiation of
37 glucocorticoids and followed for ≥ 2 years.

38 **Measurements:** PET scans were scored (0-3) at 7 vascular areas and a total vascular score
39 (TVS) was calculated. PET scans were considered positive in case of FDG uptake \geq grade 2
40 in any large vessel. Patients underwent CT imaging at diagnosis and yearly thereafter for a
41 maximum of 10 years. The association between vascular FDG uptake and aortic dimensions
42 was estimated by linear mixed effect models with random intercept and slope.

43 **Results:** The increase in ascending and descending aortic diameter and in thoracic aortic
44 volume was higher in patients with a positive PET scan compared to those without ($p=0.009$,
45 $p=0.01$, and $p=0.008$, respectively). This increase was also significantly associated with TVS
46 ($p=0.007$, $p=0.03$, and $p=0.003$, respectively). FDG uptake was not associated with an
47 increase in abdominal aortic dimensions. Thoracic aortic aneurysms were more frequently
48 observed in patients with a positive PET scan (aOR 7.19, 95%-CI 1.55-54.18, $p=0.02$).

49 **Limitations:** The lengthy inclusion and follow-up period resulted in the use of different PET
50 machines and missing data.

51 **Conclusion:** Higher TVS was associated with greater yearly increase in thoracic aortic
52 dimensions. Performing PET imaging at diagnosis may help to estimate the risk of aortic
53 aneurysm formation.

54 **Primary funding source:** none

55 **Registration:** NCT01588483

56

57

58

59 **Introduction**

60 Giant cell arteritis (GCA) is a large vessel vasculitis that preferentially affects the cranial
61 arteries, the aorta, and its proximal branches (1). The prevalence of GCA increases with age
62 and is estimated at 125-250 per 100 000 in people over 50 years old in northern Europe and
63 North America (2).

64
65 For the diagnosis of GCA, the European Alliance of Associations for Rheumatology (EULAR)
66 recommends early imaging (3). Ultrasound is recommended for the assessment of GCA with
67 cranial artery involvement with magnetic resonance imaging (MRI) as an alternative (3). Our
68 group has introduced ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)-
69 scintigraphy in the assessment of large vessel vasculitis (4,5). PET/computed tomography
70 (CT) and MRI are currently recommended for the assessment of large vessel involvement with
71 similar diagnostic accuracy (6).

72
73 Two severe complications of GCA are sudden irreversible vision loss and aortic aneurysm
74 formation and dissection. Vision loss most frequently occurs before or within the first days of
75 initiation of treatment with glucocorticoids (7). In contrast, aortic aneurysm may be present at
76 diagnosis, but typically occurs during follow-up. However, the exact timing of aortic aneurysm
77 formation in GCA patients remains unclear.

78
79 Patients with GCA have a 3 to 17-fold increased risk of developing thoracic aortic aneurysms
80 (8–11). A meta-analysis of studies with systematic imaging reported a pooled prevalence of
81 thoracic aortic aneurysm of 15% (12). GCA patients have no or only a slightly increased risk
82 of abdominal aortic aneurysms (8–11). Predictors for thoracic aneurysms were reported with
83 inconsistent results (12). However, four retrospective studies have indicated that FDG uptake
84 in large vessels at diagnosis increases the risk of developing aortic complications during follow-
85 up (13–16). Prospective studies confirming these findings are lacking. The aim of this study
86 was to evaluate the association between FDG uptake in large vessels at diagnosis and the
87 evolution of aortic dimensions in a prospective cohort of GCA patients.

88
89 **Methods**

90 *Patient population*

91 We prospectively included patients with GCA, who were evaluated by the Department of
92 General Internal Medicine of the University Hospitals Leuven between 2012 and 2020 and who
93 had undergone FDG PET imaging at diagnosis within 3 days after initiation of glucocorticoids.
94 Patients with a previous diagnosis of GCA, in whom a PET scan and yearly CT of the aorta
95 were available, were also included. Patients who were followed for less than two years were
96 excluded.

97
98 The study was conducted in accordance with the Declaration of Helsinki and approved by the
99 ethical committee of the University Hospitals Leuven. All patients gave informed consent. The
100 study was registered in advance in ClinicalTrials.gov (NCT01588483).

101
102 *Data collection*

103 We collected the following patient data from the electronic health record: age, sex, date of
104 diagnosis, duration of symptoms until diagnosis, symptoms at diagnosis, cardiovascular risk
105 factors and medication, erythrocyte sedimentation rate (ESR; mm/h), C-reactive protein (CRP;
106 mg/l), temporal artery biopsy (TAB) result, duration of follow-up, total duration (in weeks) and

107 cumulative dose in the first two years of glucocorticoid treatment, use of glucocorticoid-sparing
108 agents, relapses, aortic complications (dilatation or dissection and region), vascular stenosis,
109 vascular surgery, myocardial infarction, cerebrovascular accident (CVA), anterior ischemic
110 optic neuropathy (AION), and mortality during follow-up.

111

112 *Definitions*

113 The diagnosis of GCA was based on the judgement of two experienced clinicians (DB and
114 SV), considering all available information (clinical data, biochemical, radiological, PET and
115 TAB results, and evolution during follow-up). Relapse was defined as recurrence of clinical
116 symptoms compatible with GCA or polymyalgia rheumatica (PMR) and/or increase of
117 inflammatory markers requiring escalation of treatment. We created a cardiovascular risk score
118 by adding the following cardiovascular risk factors with a maximum of 10 points: history of
119 myocardial infarction or angor, peripheral vascular disease, and stroke were assigned 2 points;
120 diabetes, smoking, use of statins, and use of antihypertensive medication were assigned 1
121 point.

122

123 *PET imaging and analysis*

124 Patients were required to fast for at least 6 hours before intravenous injection of 4-5 MBq/kg
125 of FDG, and glycemia levels were determined in all patients (as per procedure, to be < 140
126 mg/dl). A whole-body PET scan was performed 60 min after tracer administration. PET scans
127 were performed between 2003 and 2020, acquired on a ECAT HR + PET camera, Hirez
128 Biograph 16 PET/CT, Truepoint Biograph 40 PET/CT (Siemens, Knoxville, TN, USA) or GE
129 Discovery MI 4-ring PET/CT system (GE, Milwaukee, WI, USA). Because of scan duration,
130 HR+ data were not corrected for attenuation using transmission scanning. On the PET/CT
131 systems, either a low-dose non-diagnostic CT scan or a diagnostic CT scan was performed
132 immediately before PET acquisition. Non-attenuation corrected PET images were available for
133 all included patients and attenuation-corrected PET images were only available for the patients
134 who were scanned with a PET/CT system (n=63). PET data were corrected for scatter and
135 randoms. Data were reconstructed using iterative OSEM reconstruction, with parameters
136 optimized over the years (FWHM HR+ 6-7 mm, for the Truepoint 5 mm).

137

138 Reconstructed PET images were re-evaluated visually by a specialist in nuclear medicine (LB),
139 who was blinded for all other patient information. FDG PET uptake was scored semi-
140 quantitatively at 7 vascular regions (thoracic and abdominal aorta, subclavian, axillary, carotid,
141 iliac, and femoral arteries) as 0 (no FDG uptake), 1 (minimal but not negligible FDG uptake), 2
142 (clearly increased FDG uptake), or 3 (very marked FDG uptake). PET scans were considered
143 positive in case of FDG uptake \geq grade 2 in any large vessel. Additionally, a total vascular
144 score (TVS) was calculated ranging from 0 (no vascular FDG uptake in any of the 7 vascular
145 regions) to 21 (vascular FDG uptake scored 3 in all 7 segments) (17). Subclavian, axillary,
146 carotid, iliac, and femoral arteries were counted as 1 vascular region each: when the score
147 differed from right to left artery, the highest score was taken for that vascular region. The
148 intensity of FDG uptake in affected vessels was measured by dividing TVS by the number of
149 vessels with FDG uptake \geq grade 2. In addition, to assess cranial vasculitis, the vertebral,
150 maxillary, occipital and temporal arteries were scored similarly.

151

152 *CT imaging and analysis*

153 Patients underwent a CT scan of the thorax and abdomen at diagnosis and yearly thereafter
154 for a maximum of 10 years. CT scans were preferentially performed without intravenous

155 contrast. A contrast-enhanced CT scan or PET/CT scan was used if a non-enhanced CT scan
156 was not available. The aortic diameter was measured perpendicular to the axis of blood flow
157 at six different levels (ascending aorta, aortic arch, descending thoracic aorta, suprarenal,
158 juxtarenal and infrarenal aorta) and the thoracic and abdominal aortic volumes were measured.
159 To obtain the volume, the thoracic and abdominal aorta were segmented semi-automatically
160 using MMWP Volume software (Siemens, Erlangen, Germany). Next, the volumes of both
161 parts were calculated automatically. To avoid interobserver variability, the measurements were
162 performed by the same author (diameters by LM and volumes by WC). Both were unaware of
163 the PET findings. The ascending aorta, aortic arch, descending aorta, and abdominal aorta
164 were considered aneurysmatic when the diameter was ≥ 45 , ≥ 40 , ≥ 35 and ≥ 30 mm respectively
165 (14,15).

166

167 *Statistical analysis*

168 Categorical and continuous variables were expressed as count and percentage and as mean
169 and standard deviation or median and interquartile range (IQR) as appropriate. Chi square
170 tests, Fisher's exact test, unpaired t-test, or Mann-Whitney U tests were used to compare
171 characteristics between patients with a positive and negative PET scan and between patients
172 with and without thoracic aortic aneurysm as appropriate. The associations between a positive
173 PET scan and aortic diameters and volumes were estimated by linear mixed effect models
174 with random intercept and slope in time with and without adjustment for age, sex,
175 cardiovascular risk score, CT or PET/CT scan, and intravenous contrast. These confounding
176 factors were chosen for biological and technical reasons. Subgroup analyses comparing
177 patients with a positive and negative PET scan in the thoracic and abdominal aorta were
178 performed. In addition, the association between TVS, the number of vessels with FDG uptake
179 \geq grade 2 and the intensity of FDG uptake in affected vessels on the one hand and evolution
180 of the aortic diameters and volumes on the other hand were assessed. Logistic regression
181 models were fitted to analyze the association between a positive PET scan and thoracic aortic
182 aneurysm with and without adjustment for the same variables. All statistical tests were two-
183 tailed with significance set at the $p < 0.05$ level. Statistical analysis was performed in R Studio
184 (version 2022.06.23, The R Foundation for Statistical Computing) with inclusion of the *lme4*,
185 *sjPlot*, and *ggplot2* packages.

186

187 *Role of the funding source*

188 This study received no funding.

189

190 **Results**

191 136 GCA patients underwent a PET scan between 2003 and 2020 and signed informed
192 consent. Twenty patients were excluded because they received treatment with glucocorticoids
193 for more than three days prior to PET imaging. Sixteen patients were followed less than two
194 years. Finally, 100 patients (mean age 70 years, 68% females) were included, of whom 74
195 (74%) patients had FDG uptake \geq grade 2 in any large vessel, 60 (60%) in the thoracic aorta,
196 and 49 (49%) in the abdominal aorta. In these patients, 603 CT scans were performed, of
197 which 507 (84%) non-enhanced CT scans, 14 (2%) contrast-enhanced CT scans and 82 (14%)
198 PET/CT scans. Median follow-up was 80 months (IQR 47-110). Fifteen (15%) patients
199 received glucocorticoids for less than three days prior to PET imaging; 85 (85%) were steroid-
200 naive. Median TVS was 14 (IQR 6-16, range 2-21) in the PET positive group and 0 (IQR 0-1,
201 range 0-3) in the PET negative group. FDG uptake \geq grade 2 was most frequently observed in
202 the subclavian arteries (64%), followed by ascending aorta (59%), aortic arch (57%),

203 descending aorta (57%), abdominal aorta (49%), carotid arteries (48%), axillary arteries (48%),
204 iliac arteries (22%), and femoral arteries (20%). Forty eight percent of patients had increased
205 FDG uptake in the cranial arteries, all of whom had FDG uptake in the vertebral arteries. The
206 maxillary, temporal, and occipital arteries were affected in 36%, 15%, and 11% respectively.
207

208 The baseline characteristics are presented in Table 1. Patients with a positive PET scan were
209 younger (68 versus 74 years, $p=0.001$) and more frequently female (77% versus 42%,
210 $p=0.001$) compared to those with a negative PET scan. The symptom duration until diagnosis
211 was significantly longer in patients with a positive PET scan (8 versus 3 weeks, $p<0.001$).
212 Patients without vascular FDG uptake more frequently had cranial symptoms (96% versus
213 69%, $p=0.006$) and tended to have more PMR (54% versus 34%, $p=0.07$), whereas those with
214 vascular FDG uptake more often had constitutional symptoms (95% versus 65%, $p<0.001$).
215 There were no significant differences in cardiovascular risk factors, proportion of patients with
216 a positive temporal artery biopsy, or inflammatory markers between the PET positive and PET
217 negative group.
218

219 The increase in ascending and descending aortic diameter and in thoracic aortic volume was
220 higher in patients with a positive PET scan compared to those without ($p=0.009$, $p=0.01$ and
221 $p=0.008$, respectively) (Table 2 and Supplementary Tables 1 and 2). In patients with a positive
222 PET scan in the thoracic aorta, the increase was only significantly higher in the ascending
223 aortic diameter and in thoracic aortic volume (both $p=0.005$) (Table 2 and Supplementary
224 Tables 3 and 4). However, there was also a trend to a greater increase in the diameter of the
225 descending aorta and aortic arch ($p=0.06$ and $p=0.07$, respectively). Vascular FDG uptake was
226 not associated with an increase in abdominal aortic diameters nor volume (Table 2 and
227 Supplementary Tables 5 and 6). The thoracic aortic diameters and volume were positively
228 associated with TVS (Table 3, Figure 1 and Supplementary Tables 7 and 8). There was no
229 significant association between the abdominal aortic diameters and volume on the one hand
230 and TVS on the other hand. The ascending and descending aortic diameter and thoracic aortic
231 volume were also positively associated with the number of vessels with FDG uptake \geq grade
232 2 and with the intensity of FDG uptake in affected vessels (Supplementary Tables 9-12). As
233 expected, TVS, the number of affected vessels, and the intensity of FDG uptake in affected
234 vessels are correlated with each other, with the strongest correlation between TVS and the
235 number of affected vessels (Supplementary Table 13).
236

237 Twenty-one patients developed an aortic aneurysm, which was already present on the first CT
238 scan in six patients. The median time since diagnosis to develop an aortic aneurysm was 37
239 months (IQR 19-60) for any aneurysm and 40 months (IQR 18-61) for thoracic aortic aneurysm.
240 Eighteen patients had an aneurysm in the descending aorta, five in the ascending aorta, five
241 in the aortic arch, and four in the abdominal aorta. In three of the four patients with an
242 abdominal aortic aneurysm, the aneurysm was located in the suprarenal aorta and these
243 patients also had a thoracic aortic aneurysm. The patient with an isolated abdominal aortic
244 aneurysm had an infrarenal aneurysm. Logistic regression analysis revealed that thoracic
245 aortic aneurysms occurred more frequently in patients with a positive PET scan (24% versus
246 8%, aOR 7.19, 95%-CI 1.55-54.18, $p=0.02$) and in patients with a positive PET scan in the
247 thoracic aorta (27% versus 10%, aOR 6.06, 95%-CI 1.68-27.62, $p=0.01$) (Supplementary
248 Tables 14 and 15). Aortic aneurysm occurred in 16 of the 18 (89%) PET positive patients in a
249 region with FDG uptake at diagnosis. Two patients with high TVS (15 and 16, maximum 21)
250 needed elective surgery for ascending aortic aneurysm. Histopathological examination showed

251 degenerative changes, cystic media necrosis and mild lymphocytic inflammation in the
252 adventitia in both patients and also in the media in one patient.

253

254 As an exploratory analysis, we examined differences between patients with and without
255 thoracic aneurysms (Table 4). Patients who developed a thoracic aneurysm, tended to have
256 higher TVS (14 versus 6, $p=0.05$) with both higher number of affected vessels (5 versus 2,
257 $p=0.03$), and higher intensity of FDG uptake in affected vessels (2.8 versus 2.7, $p=0.04$). They
258 also had a longer symptom duration until diagnosis (8 versus 6 weeks, $p=0.04$), and higher
259 inflammatory markers at diagnosis (CRP 121 versus 78 mg/l, $p=0.02$ and ESR 98 versus 67
260 mm/h, $p=0.04$). There were no significant differences in age, sex, cardiovascular risk factors,
261 symptoms at diagnosis, temporal artery biopsy results, duration of glucocorticoids, cumulative
262 dose of glucocorticoids in the first two years, use of glucocorticoid-sparing agents, relapse rate,
263 cardiovascular events during follow-up, or mortality.

264

265 **Discussion**

266 In this prospective study, we found that GCA patients with a positive PET scan had a greater
267 increase in ascending and descending aortic diameter and thoracic aortic volume compared
268 to those with a negative scan. There were no differences in abdominal aortic diameters and
269 volume. In addition, higher TVS was associated with greater yearly increase in thoracic aortic
270 diameters and volume. In patients without elevated vascular FDG uptake, the increase in aortic
271 diameters seems to be similar to the general population with a reported yearly increase of
272 about 0.1-0.2 mm (18). Vascular and more specifically thoracic aortic FDG uptake at diagnosis
273 was an independent risk factor for developing thoracic aortic aneurysms.

274

275 These findings are consistent with earlier retrospective studies (13–16). Our group first showed
276 that patients with aortic FDG uptake at diagnosis had a significantly larger ascending and
277 descending aortic diameter and thoracic aortic volume during follow-up (13). In a multicenter
278 study of de Booysson et al. 9% of patients developed aortic dilatation, all of whom had FDG
279 uptake in large vessels at diagnosis or during follow-up (14). Afterwards, they confirmed that
280 large vessel inflammation is a predictor of aortic dilatation in a larger, multicenter, retrospective
281 cohort (15). Muratore et al. reported significantly larger thoracic and abdominal diameters in
282 patients with FDG uptake grade 3 compared to those with FDG uptake \leq grade 2 (16).

283

284 The mechanism of aneurysm formation in GCA patients remains unclear. It is sometimes
285 hypothesized that persistent subclinical vasculitis activity leads to cumulative damage to the
286 aortic wall (12,19). However, histopathological examination of the aorta after surgery mostly
287 revealed extensive disruption of elastic fibers in the media with only mild and scattered
288 inflammation in the media and/or adventitia (20–22), which we also found in two patients who
289 required elective surgery for an ascending aortic aneurysm in our cohort. In 89% of PET
290 positive patients aortic dilatation occurred in a vascular region with elevated FDG uptake at
291 diagnosis. In addition, we found a dose-response relation with a positive association between
292 TVS and thoracic aortic diameters and volume. Both the number of vessels with FDG uptake
293 \geq grade 2 and the intensity of FDG uptake in affected vessels were associated with the
294 evolution in the ascending and descending aortic diameter and thoracic aortic volume.
295 However, the extent and the intensity of vessel involvement were correlated, which we assume
296 to be related to patients with severe large vessel vasculitis having both larger extent of affected
297 vessels and a higher intensity of inflammation in the affected vessels. Moreover, patients who
298 developed a thoracic aneurysm, had a longer symptom duration until diagnosis and had higher

299 inflammatory markers at diagnosis. Inflammatory markers were also higher in patients with
300 aortic aneurysms in the study of Gonzalez-Gay et al. (23), but this was not significant in several
301 other studies (13,14,16,19,24,25). Blockmans et al. and Nuenninghoff et al. also found a longer
302 symptom duration until diagnosis in patients with aortic dilatation (13,26), but this was not
303 confirmed in two other studies (19,23). There were no significant differences in cardiovascular
304 risk factors in patients with and without thoracic aneurysms. Our findings suggest that the
305 intensity, duration and extent of initial inflammation rather than the persistence of inflammatory
306 activity determines the risk of subsequent aortic dilatation. This intense inflammation probably
307 weakens the aortic wall, which then undergoes progressive dilatation due to deficient vascular
308 remodeling and mechanical forces.

309

310 There is no consensus on the screening for the development of aortic aneurysms in GCA
311 patients. EULAR and American College of Rheumatology (ACR) guidelines currently do not
312 recommend routinely screening for aortic dilatation (3,27,28). In contrast, the American Heart
313 Association (AHA)/American College of Cardiology (ACC) Joint Committee recommends
314 annual surveillance imaging with CT, MRI, or PET/CT (29). This study confirms that vascular
315 FDG uptake is an independent predictor of thoracic aortic aneurysms with a higher increase in
316 thoracic aortic diameters and volume in patients with higher TVS. One fourth of patients with
317 a positive PET scan developed a thoracic aortic aneurysm. These aneurysms most frequently
318 occurred in the descending aorta in a median time since diagnosis of 40 months, but the two
319 patients who needed surgery, had an ascending aortic aneurysm. Follow-up of aortic
320 dimensions seems to be warranted in GCA patients, especially in those with high intensity and
321 broad extent of vascular inflammation. However, the added value of screening and the interval
322 required should be addressed in future studies.

323

324 Consistent with previous studies (15,30,31), we found that patients with a positive PET scan
325 were younger, were more frequently female, and had a longer symptom duration until
326 diagnosis. Patients with vascular FDG uptake more often had constitutional symptoms,
327 whereas cranial symptoms and PMR more frequently occurred in those without vascular FDG
328 uptake. However, these symptoms are not specific enough to differentiate patients with and
329 without large vessel vasculitis clinically. Thus, to estimate the future risk of aortic aneurysm
330 formation, performing PET imaging at diagnosis before or shortly after the start of
331 glucocorticoid treatment in GCA patients would be advisable.

332

333 Strengths of this study include that it is the first prospective study which addresses the impact
334 of vascular FDG uptake on the evolution of aortic dimensions. In addition, a large cohort of
335 GCA patients was followed for a long time in this study. Our study also has several limitations.
336 First, due to the long inclusion period PET scans were performed on different PET systems
337 with increasing device quality over time. In addition, CT scans were preferentially performed
338 without intravenous contrast, but a contrast-enhanced CT scan or a PET/CT scan was used if
339 a non-enhanced CT scan was not available. However, we corrected for this in the linear mixed
340 model and logistic regression analyses. Third, due to the long follow-up a substantial number
341 of CT scans were missing. Fourth, this was a single-center study, which probably limits the
342 generalizability. Finally, the treatment was at the discretion of the physician, so we cannot
343 exclude an effect of differences in treatment on the evolution of aortic dimensions. However,
344 the duration of glucocorticoid treatment, the cumulative glucocorticoid dose in the first two
345 years and the use of glucocorticoid-sparing agents were not significantly different in patients
346 with and without thoracic aneurysms.

347

348 In conclusion, higher TVS was associated with greater yearly increase in thoracic aortic
349 diameters and volume. Vascular FDG uptake was not associated with an increase in
350 abdominal aortic diameters nor volume. Vascular and more specifically thoracic aortic FDG
351 uptake at diagnosis is an independent risk factor for developing thoracic aortic aneurysms in
352 GCA patients. In addition to diagnostic information, performing PET imaging at diagnosis in
353 GCA patients would help to estimate the future risk of aortic aneurysm formation. Follow-up of
354 aortic dimensions may be warranted in patients with thoracic aortic FDG uptake or a high TVS.
355

356 **Conflict of Interest**

357 The authors declare that the research was conducted in the absence of any commercial or
358 financial relationships that could be construed as a potential conflict of interest.
359

360 **Author Contributions**

361 LM: Conceptualization, Methodology, Validation, Investigation, Formal analysis, Writing –
362 Original Draft, Writing – Review & Editing, Visualization; WC: Conceptualization, Methodology,
363 Validation, Investigation, Writing – Review & Editing; LB: Methodology, Validation,
364 Investigation, Writing – Review & Editing; AB: Conceptualization, Methodology, Writing –
365 Review & Editing; GM: Methodology, Formal analysis, Writing – Review & Editing; SV:
366 Investigation, Writing – Review & Editing, Supervision; KVL: Writing – Review & Editing,
367 supervision; EC: Investigation, Writing – Review & Editing, DB: Conceptualization,
368 Methodology, Investigation, Writing – Review & Editing, Supervision
369

370 **References**

- 371 1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised
372 International Chapel Hill consensus conference nomenclature of vasculitides. *Arthritis*
373 *Rheum.* 2013;65(1):1–11.
- 374 2. Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. *Nat*
375 *Rev Rheumatol.* 2022;18(1):22–34.
- 376 3. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR
377 recommendations for the use of imaging in large vessel vasculitis in clinical practice.
378 *Ann Rheum Dis.* 2018;77(5):636–43.
- 379 4. Blockmans D, Maes A, Stroobants S, Nuyts J, Bormans G, Knockaert D, et al. New
380 arguments for a vasculitic nature of polymyalgia rheumatica using positron emission
381 tomography. *Rheumatology.* 1999;38(5):444–7.
- 382 5. Blockmans D, Stroobants S, Maes A, Mortelmans L. Positron Emission Tomography in
383 Giant Cell Arteritis and Polymyalgia Rheumatica : Evidence for Inflammation of the
384 Aortic Arch. *Am J Med.* 2000;108(3):246–9.
- 385 6. Hellmich B, Agueda A, Monti S, Buttgereit F, De Boysson H, Brouwer E, et al. 2018
386 Update of the EULAR recommendations for the management of large vessel
387 vasculitis. *Ann Rheum Dis.* 2020;79(1):19–130.
- 388 7. Soriano A, Muratore F, Pipitone N, Boiardi L, Cimino L, Salvarani C. Visual loss and
389 other cranial ischaemic complications in giant cell arteritis. *Nat Rev Rheumatol.* 2017
390 Aug;13(8):476–84.
- 391 8. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and
392 dissection in giant cell (temporal) arteritis: A population-based study. *Ann Intern Med.*
393 1995;122(7):502–7.
- 394 9. Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative
395 risk of aortic aneurysm in patients with giant cell arteritis compared with the general
396 population of the UK. *Ann Rheum Dis.* 2015;74(1):129–35.
- 397 10. Molloy ES, Kirchner H, Murray P. Cardiovascular outcomes and in-hospital mortality in

- 398 giant cell arteritis. *APMIS*. 2009;117(Suppl s127):83–4.
- 399 11. Therkildsen P, De Thurah A, Nielsen BD, Hansen IT, Eldrup N, Nørgaard M, et al.
400 Increased risk of thoracic aortic complications among patients with giant cell arteritis:
401 A nationwide, population-based cohort study. *Rheumatol*. 2022;61(7):2931–41.
- 402 12. Mackie SL, Hensor EMA, Morgan AW, Pease CT. Should i send my patient with
403 previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature
404 review and meta-analysis. *Ann Rheum Dis*. 2014;73(1):143–8.
- 405 13. Blockmans D, Coudyzer W, Vanderschueren S, Stroobants S, Loeckx D, Heye S, et
406 al. Relationship between fluorodeoxyglucose uptake in the large vessels and late
407 aortic diameter in giant cell arteritis. *Rheumatology*. 2008;47(8):1179–84.
- 408 14. De Boysson H, Liozon E, Lambert M, Parienti JJ, Artigues N, Geffray L, et al. 18 F-
409 fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic
410 complications in giant-cell arteritis. *Medicine (Baltimore)*. 2016;95(26).
- 411 15. de Boysson H, Daumas A, Vautier M, Parienti J-J, Liozon E, Lambert M, et al. Large-
412 vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549
413 patients. *Autoimmun Rev*. 2018 Apr;17(4):391–8.
- 414 16. Muratore F, Crescentini F, Spaggiari L, Pazzola G, Casali M, Boiardi L, et al. Aortic
415 dilatation in patients with large vessel vasculitis: A longitudinal case control study
416 using PET/CT. *Semin Arthritis Rheum*. 2019;48(6):1074–82.
- 417 17. Blockmans D, Ceuninck L de, Vanderschueren S, Knockaert D, Mortelmans L,
418 Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in
419 giant cell arteritis: a prospective study of 35 patients. *Arthritis Care Res (Hoboken)*.
420 2006;55(1):131–7.
- 421 18. Rogers IS, Massaro JM, Truong QA, Mahabadi AA, Kriegel MF, Fox CS, et al.
422 Distribution, Determinants, and Normal Reference values of Thoracic and Abdominal
423 Aortic Diameters by Computed Tomography (From the Framingham Heart Study). *Am
424 J Cardiol*. 2013;111(10):1510–6.
- 425 19. García-Martínez A, Hernández-Rodríguez J, Arguis P, Paredes P, Segarra M, Lozano
426 E, et al. Development of aortic aneurysm/dilatation during the followup of patients with
427 giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed
428 patients. *Arthritis Care Res*. 2008;59(3):422–30.
- 429 20. Zehr KJ, Mathur A, Orszulak TA, Mullany CJ, Schaff H V. Surgical treatment of
430 ascending aortic aneurysms in patients with giant cell aortitis. *Ann Thorac Surg*. 2005
431 May;79(5):1512–7.
- 432 21. García-Martínez A, Arguis P, Prieto-González S, Espígol-Frigolé G, Alba MA, Butjosa
433 M, et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis
434 screened for aortic structural damage (aneurysm or dilatation). *Ann Rheum Dis*.
435 2014;73(10):1826–32.
- 436 22. Lie JT. Aortic and extracranial large vessel giant cell arteritis: A review of 72 cases
437 with histopathologic documentation. *Semin Arthritis Rheum*. 1995;24(6):422–31.
- 438 23. Gonzalez-Gay MA, Garcia-Porrua C, Piñeiro A, Pego-Reigosa R, Llorca J, Hunder
439 GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis
440 from northwestern Spain: A population-based study. *Medicine (Baltimore)*.
441 2004;83(6):335–41.
- 442 24. Kermani TA, Warrington KJ, Crowson CS, Ytterberg SR, Hunder GG, Gabriel SE, et
443 al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of
444 the incidence-trends and prognosis. *Ann Rheum Dis*. 2013;72(12):1989–94.
- 445 25. Espitia O, Blonz G, Urbanski G, Landron C, Connault J, Lavigne C, et al. Symptomatic
446 aortitis at giant cell arteritis diagnosis: a prognostic factor of aortic event. *Arthritis Res
447 Ther*. 2021 Jan;23(1):14.
- 448 26. Nueninghoff DM, Hunder GG, Christianson TJH, McClelland RL, Matteson EL.
449 Incidence and Predictors of Large-Artery Complication (Aortic Aneurysm, Aortic
450 Dissection, and/or Large-Artery Stenosis) in Patients with Giant Cell Arteritis: A
451 Population-Based Study over 50 Years. *Arthritis Rheum*. 2003;48(12):3522–31.
- 452 27. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American

- 453 College of Rheumatology/Vasculitis Foundation Guideline for the Management of
454 Giant Cell Arteritis and Takayasu Arteritis. *Arthritis Rheumatol* (Hoboken, NJ). 2021
455 Aug;73(8):1349–65.
- 456 28. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018
457 Update of the EULAR recommendations for the management of large vessel
458 vasculitis. *Ann Rheum Dis*. 2020;79(1):19–30.
- 459 29. Isselbacher EM, Preventza O, Hamilton Black J, Augoustides JG, Beck AW, Bolen
460 MA, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic
461 Disease. *J Am Coll Cardiol*. 2022;80(24):e223–393.
- 462 30. Muratore F, Boiardi L, Restuccia G, Cavazza A, Catanoso M, Macchioni P, et al.
463 Relapses and long-term remission in large vessel giant cell arteritis in northern Italy:
464 Characteristics and predictors in a long-term follow-up study. *Semin Arthritis Rheum*.
465 2020;50(4):549–58.
- 466 31. Tomelleri A, Campochiaro C, Sartorelli S, Farina N, Baldissera E, Dagna L. Presenting
467 features and outcomes of cranial-limited and large-vessel giant cell arteritis: a
468 retrospective cohort study. *Scand J Rheumatol*. 2022;51(1):59–66.
469

470 **Tables and figures**471 **Table 1:** Baseline characteristics of patients with (PET positive) and without (PET negative)
472 vascular FDG uptake \geq grade 2

Characteristics	Total (n = 100)	PET positive (n = 74)	PET negative (n = 26)	p-value
Age at inclusion, years, mean (SD)	70 (8)	68 (7)	74 (8)	0.001
Sex, no. of females, n (%)	68 (68)	57 (77)	11 (42)	0.001
Symptom duration until diagnosis, weeks, median (IQR)	6 (3-14)	8 (4-17)	3 (2-5)	< 0.001
Cardiovascular risk factors/events				
o Active or past tobacco use, n (%)	46 (49) ⁶	35 (49) ²	11 (50) ⁴	0.91
o Antihypertensive medication, n (%)	47 (47)	32 (43)	15 (58)	0.20
o Diabetes mellitus, n (%)	5 (5)	3 (4)	2 (8)	0.60
o Statin use, n (%)	30 (30)	20 (27)	10 (38)	0.27
o History of stroke, n (%)	4 (2)	2 (3)	2 (8)	0.28
o History of myocardial infarction or angor, n (%)	2 (2)	2 (3)	0 (0)	1
o History of peripheral vascular, disease, n (%)	2 (2)	1 (1)	1 (4)	0.45
o Cardiovascular risk score, median (IQR)	1 (0-2)	1 (0-2)	1 (1-2)	0.35
Symptoms at diagnosis				
o Cranial symptoms, n (%)	76 (76)	51 (69)	25 (96)	0.006
o PMR, n (%)	37 (37)	25 (34)	14 (54)	0.07
o Constitutional symptoms, n (%)	87 (87)	70 (95)	17 (65)	< 0.001
o Limb claudication, n (%)	4 (4)	4 (5)	0 (0)	0.57
Laboratory tests				
o ESR, mm/h, median (IQR)	69 (48-105) ¹⁴	70 (47-109) ¹¹	66 (52-90) ³	0.45
o CRP, mg/l, median (IQR)	87 (43-130)	86 (45-125)	92 (43-136)	0.70
Positive temporal artery biopsy, n (%)	49 (63) ²²	31 (60) ²²	19 (73)	0.24
Duration of follow-up, months, median (IQR)	80 (47-110)	75 (43-107)	91 (59-117)	0.26

473 **Abbreviations:** CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; FDG, fluorodeoxyglucose; IQR, interquartile
474 range; no., number; PET, positron emission tomography; PMR, polymyalgia rheumatica; SD, standard deviation
475 Number of missing values are reported in superscript.
476
477

478 **Table 2:** Evolution of the aortic diameters (in mm) and volumes (in cm³) per year in patients with (PET positive) and without (PET negative)
 479 FDG uptake ≥ grade 2 in large vessels

FDG uptake ≥ grade 2 in any large vessel						
	Crude regression coefficient (95% CI)*		p-value	Adjusted regression coefficient (95% CI)°		p-value
	PET negative	PET positive		PET negative	PET positive	
Volume of thoracic aorta	3.62 (0.69-6.57)	7.84 (6.07-9.61)	0.02	2.39 (-0.42-5.20)	6.82 (5.11-8.55)	0.008
Volume of abdominal aorta	-0.38 (-1.29-0.54)	-0.73 (-1.27- -0.20)	0.52	0.27 (-0.48-1.04)	0.12 (-0.33-0.57)	0.73
Diameter of thoracic aorta						
○ Ascending aorta	0.06 (-0.14-0.26)	0.34 (0.22-0.46)	0.02	0.10 (-0.11-0.30)	0.41 (0.29-0.53)	0.009
○ Aortic arch	0.20 (0.04-0.35)	0.31 (0.22-0.41)	0.21	0.21 (0.05-0.37)	0.35 (0.25-0.45)	0.14
○ Descending aorta	0.11 (-0.05-0.27)	0.34 (0.24-0.44)	0.02	0.11 (-0.06-0.27)	0.34 (0.25-0.45)	0.01
Diameter of abdominal aorta						
○ Suprarenal aorta	0.08 (-0.02-0.19)	0.12 (0.06-0.18)	0.53	0.07 (-0.04-0.17)	0.11 (0.04-0.17)	0.51
○ Juxtarenal aorta	0.12 (0.00-0.23)	0.10 (0.03-0.16)	0.78	0.14 (0.03-0.25)	0.14 (0.07-0.21)	0.98
○ Infrarenal aorta	0.15 (0.07-0.23)	0.07 (0.03-0.12)	0.10	0.15 (0.07-0.23)	0.08 (0.03-0.12)	0.11
FDG uptake ≥ grade 2 in thoracic aorta						
	Crude regression coefficient (95% CI)*		p-value	Adjusted regression coefficient (95% CI)°		p-value
	PET negative	PET positive		PET negative	PET positive	
Volume of thoracic aorta	4.27 (1.90-6.66)	8.35 (6.41-10.30)	0.009	3.11 (0.83-5.40)	7.34 (5.46-9.24)	0.005
Diameter of thoracic aorta						
○ Ascending aorta	0.11 (-0.05-0.27)	0.37 (0.24-0.50)	0.01	0.14 (-0.02-0.31)	0.45 (0.31-0.58)	0.005
○ Aortic arch	0.21 (0.08-0.33)	0.33 (0.23-0.43)	0.13	0.22 (0.09-0.35)	0.37 (0.27-0.48)	0.07
○ Descending aorta	0.19 (0.06-0.32)	0.34 (0.23-0.45)	0.09	0.18 (0.05-0.32)	0.35 (0.24-0.46)	0.06
FDG uptake ≥ grade 2 in abdominal aorta						
	Crude regression coefficient (95% CI)*		p-value	Adjusted regression coefficient (95% CI)°		p-value
	PET negative	PET positive		PET negative	PET positive	
Volume of abdominal aorta	-0.49 (-1.14-0.16)	-0.78 (-1.44- -0.14)	0.52	0.08 (-0.46-0.61)	0.23 (-0.33-0.78)	0.68
Diameter of abdominal aorta						
○ Suprarenal aorta	0.09 (0.01-0.16)	0.13 (0.06-0.21)	0.37	0.07 (-0.00-0.14)	0.12 (0.04-0.20)	0.33
○ Juxtarenal aorta	0.10 (0.02-0.18)	0.10 (0.02-0.18)	0.95	0.13 (0.05-0.20)	0.15 (0.07-0.23)	0.70
○ Infrarenal aorta	0.13 (0.07-0.18)	0.06 (0.01-0.12)	0.11	0.12 (0.07-0.18)	0.06 (0.00-0.12)	0.12

480 * Linear mixed model without adjustment for confounders

481 ° Linear mixed model adjusted for age, sex, cardiovascular risk score, CT or PET/CT scan, and intravenous contrast

482 **Abbreviations:** 95% CI, 95% confidence interval; FDG, fluorodeoxyglucose; PET, positron emission tomography

483

484 **Table 3:** Association between total vascular score and the evolution in aortic diameters (mm)
 485 and volumes (cm³)

	Crude regression coefficient of interaction term ⁺ (95% CI)	p-value for interaction term ¹	Adjusted regression coefficient of interaction term ^{o+} (95% CI)	p-value for interaction term ¹
Volume of thoracic aorta	0.31 (0.09-0.52)	0.005	0.31 (0.11 – 0.52)	0.003
Volume of abdominal aorta	-0.03 (-0.10-0.04)	0.38	0.00 (-0.05 – 0.06)	0.95
Diameter of thoracic aorta				
○ Ascending aorta	0.02 (0.00-0.03)	0.03	0.02 (0.01 – 0.04)	0.007
○ Aortic arch	0.01 (0.00-0.02)	0.11	0.01 (0.00 – 0.02)	0.05
○ Descending aorta	0.01 (0.00-0.02)	0.04	0.01 (0.00 – 0.03)	0.03
Diameter of abdominal aorta				
○ Suprarenal aorta	0.00 (-0.00-0.01)	0.34	0.00 (-0.00 – 0.01)	0.29
○ Juxtarenal aorta	0.00 (-0.01-0.01)	0.59	0.00 (-0.00 – 0.01)	0.31
○ Infrarenal aorta	-0.01 (-0.01- -0.00)	0.05	-0.01 (-0.01 – -0.00)	0.05

486 * Linear mixed model without adjustment for confounders

487 ° Linear mixed model adjusted for age, sex, cardiovascular risk score, CT or PET/CT scan, and intravenous contrast

488 + Interaction between evolution in time (in year) and total vascular score

489 **Abbreviations:** 95% CI, 95% confidence interval

490

Table 4: Characteristics of patients with and without thoracic aneurysm


Characteristics	Total (n = 100)	Thoracic aneurysm (n = 20)	No thoracic aneurysm (n = 80)	p-value
Age at inclusion, years, mean (SD)	70 (8)	69.5 (6)	70 (8)	0.80
Sex, no. of females, n (%)	68 (68)	11 (55)	57 (71)	0.16
Symptom duration until diagnosis, week, median (IQR)	6 (3-14)	8 (6-18)	6 (3-13)	0.04
Cardiovascular risk factors/events at diagnosis				
o Active or past tobacco use, n (%)	46 (49) ⁶	13 (65)	33 (45) ⁶	0.11
o Antihypertensive medication, n (%)	47 (47)	10 (50)	37 (46)	0.76
o Statin use, n (%)	30 (30)	5 (25)	25 (31)	0.58
o Diabetes mellitus, n (%)	5 (5)	0 (0)	5 (6)	0.59
o History of stroke, n (%)	4 (2)	1 (5)	3 (4)	1
o History of myocardial infarction or angor, n (%)	2 (2)	0 (0)	2 (3)	1
o History of peripheral vascular, disease, n (%)	2 (2)	0 (0)	2 (3)	1
o Betablocker at diagnosis, n (%)	34 (34)	8 (40)	26 (33)	0.53
o Betablocker during follow-up, n (%)	49 (49)	13 (65)	36 (45)	0.11
o Cardiovascular risk score, median (IQR)	1 (0-2)	1 (1-2)	1 (0-2)	0.56
Symptoms at diagnosis				
o Cranial symptoms, n (%)	76 (76)	12 (60)	64 (80)	0.08
o PMR, n (%)	39 (39)	4 (20)	35 (44)	0.05
o Constitutional symptoms, n (%)	85 (85)	19 (95)	68 (85)	0.46
o Limb claudication, n (%)	4 (4)	1 (5)	3 (4)	1
Laboratory tests at diagnosis				
o ESR, mm/h, median (IQR)	69 (48-105) ¹⁴	98 (57-126) ²	67 (43-104) ¹²	0.04
o CRP, mg/l, median (IQR)	87 (43-130)	121 (89-146)	78 (41 – 123)	0.02
Positive temporal artery biopsy, n (%)	49 (63) ²²	6 (46) ⁷	44 (68) ¹⁵	0.20
PET results				
o Positive PET, n (%)	74 (74.0)	18 (90.0)	56 (70.0)	0.07
o Positive PET in thoracic aorta, n (%)	60 (60.0)	16 (80.0)	44 (55.0)	0.04
o TVS, median (IQR)	8 (2-14)	14 (8-16)	6 (1-14)	0.05
o Number of vessels with FDG uptake ≥ grade 2, median (IQR)	3 (0-5)	5 (4-6)	2 (0-5)	0.03
o Intensity of FDG uptake in affected vessels, median (IQR) ^o	2.8 (0-3)	2.8 (2.5-3.0)	2.7 (0-2.9)	0.04
Treatment				
o Duration of GC treatment, months, median (IQR)	34 (24-65) ³	44 (25-94) ¹	34 (23-60) ²	0.32
o Cumulative GC dose in first 2 years after diagnosis, g methylprednisolone, mean (SD)	4.7 (1.4) ⁶	4.8 (1.5)	4.7 (1.3) ⁵	0.73
o Use of glucocorticoid-sparing agents during follow-up, n (%)	32 (33) ²	7 (37) ¹	25 (32) ¹	0.66
Duration of follow-up, months, median (IQR)	80 (47-110)	107 (74-123)	71 (41-99)	0.01
Relapse, n (%)	68 (68)	15 (75)	53 (66)	0.10
Cardiovascular event during follow-up				
o Aortic dissection, n (%)	0 (0)	0 (0)	0 (0)	/
o Vascular stenosis, n (%)	14 (14)	5 (25)	9 (11)	0.15
o Vascular surgery, n (%)	7 (7)	2 (10)	5 (6)	0.62
o Myocardial infarction, n (%)	2 (2)	0 (0)	2 (3)	1
o CVA, n (%)	10 (10)	3 (15)	7 (9)	0.41
o AION, n (%)	2 (2)	0 (0)	2 (3)	1
Mortality, n (%)	13 (13)	3 (15)	10 (13)	0.72

492 **Abbreviations:** AION, anterior ischemic optic neuropathy; CRP, C-reactive protein; CVA, cerebrovascular accident; ESR,
493 erythrocyte sedimentation rate; FDG, fluorodeoxyglucose; GC, glucocorticoids; IQR, interquartile range; no., number; PET,
494 positron emission tomography; PMR, polymyalgia rheumatica; SD, standard deviation; TVS, total vascular score
495 Number of missing values are reported in superscript.

496 ^o Calculated as total vascular score divided by the number of vessels with FDG uptake ≥ grade 2
497

498 **Figure 1:** Association between total vascular score and the evolution in (A) volume of
 499 thoracic aorta, (B) diameter of ascending aorta, (C) diameter of aortic arch, (D) diameter of
 500 descending aorta, (E) volume of abdominal aorta, (F) diameter of suprarenal aorta, (G)
 501 diameter of juxtarenal aorta, and (H) diameter of infrarenal aorta. The linear mixed models
 502 were adjusted for age, sex, cardiovascular risk score, CT or PET/CT scan, and intravenous
 503 contrast.

504 **Abbreviations:** TVS, total vascular score



505
 506
 507
 508